AI-driven chemistry retrosynthesis tool to advance drug discovery

In a bid to help to bring drugs to market for patients most in need, Elsevier, a global research publishing and information analytics provider.

Is collaborating with Pending.AI (PAI), a start-up focused on developing artificial intelligence (AI) solutions for drug discovery, to develop the predictive retrosynthesis tool based on deep learning to support innovation in synthetic and medicinal chemistry. The tool was initially developed via Elsevier’s R&D Collaboration Network and is now being integrated into Elsevier’s flagship chemistry solution, Reaxys, combining Reaxys’ content with cutting-edge AI and machine learning technologies developed by PAI.

The Reaxys-PAI Predictive Retrosynthesis solution uses a model that incorporates deep neural networks trained on Reaxys data. The results are found using a Monte Carlo tree search approach to quickly discover promising candidate routes. Hundreds of thousands of reaction rules (>400,000) are algorithmically extracted from the Reaxys source data (>15 million single-step organic reactions), enabling it to be non-reliant on hand-encoded rules that are typically used in other solutions.

The tool has been tested rigorously by the world’s leading pharmaceutical and chemical companies and has been demonstrated to provide scientifically robust, diverse and innovative synthetic route suggestions. It is a valuable tool that is easy and intuitive to use and supports the needs of the business and researchers by being a very good assistant and idea generator. The predictive retrosynthesis solution has been trained on both positive and negative reaction data and solves synthesis design questions for novel molecules with direct links to experimental reactions available in the most trusted chemistry solution Reaxys. The predictive model training and creation is fast, allowing it to ‘self-learn’ from the rapidly ever-growing chemistry knowledge. Reaxys-PAI Predictive Retrosynthesis can be further augmented by training on proprietary chemistry reaction data, including a customer’s own reaction dataset and building block library.

Prof. Dr. Mark Waller, Director at Pending.AI, said: “AI is becoming essential as scientific data grows in abundance. Our mission is to develop pragmatic solutions using AI and machine learning to empower scientists to advance drug discovery and development of other chemical compounds. We are proud to be working with Elsevier to meet this goal. The Reaxys-PAI Predictive Retrosynthesis tool will complement the knowledge of scientists and teams and help them to rapidly make more informed decisions.”

Ivan Krstic, Director Product Management, Life Science Solutions at Elsevier, said: “AI is set to revolutionize the domain of chemical design and synthesis of small molecules. Over the past decade, the exponential growth in chemistry data; the ability to curate and harmonize data; coupled with advancements in computational and digital technologies such as deep learning has provided ideal grounds for addressing the problem of computer-aided synthesis design.

“We are very happy and honoured that this innovative work is enabled by a partnership between Elsevier and PAI to provide a best-in-class predictive retrosynthesis solution which combines high quality Reaxys reaction data with industry-leading predictive algorithms developed by PAI,” added Ivan. “We have strong evidence that the addition of AI-based retrosynthesis to Reaxys can help drive innovation, save researchers considerable time and radically change how we approach chemical synthesis, but I also want to share with my fellow chemists our strong belief that AI won’t replace chemists, instead it will support chemists and their decision making by paving the way in a more and more complex landscape of data.”

Source  pharmafield.co.uk/pharma_news/ai-driven-chemistry-retrosynthesis-tool-to-advance-drug-discovery/

Follow Share Talk


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned
Share via
Copy link
Malcare WordPress Security